Address
280 East Grand Avenue
South San Francisco, CA 94080
United States of America (the)
Phone
(650) 231-6625
Website
Sector
Healthcare
Industry
Biotechnology
Employees
223
First IPO Date
June 28, 2024
| Name | Title | Pay | Year Born |
| Martin Babler | President, Chief Executive Officer & Chairman | 1.21M | 1965 |
| Roy C. Hardiman | Chief Business & Strategy Officer | 619,841 | 1960 |
| Jorn Drappa | Chief Medical Officer & Head of Research and Development | 817,058 | 1965 |
| David Goldstein | Chief Scientific Officer | 821,186 | 1966 |
| John R. Schroer | Chief Financial Officer | 0 | 1965 |
| Mark Bradley | Chief Development Officer | 0 | 1966 |
| Grace Halteh | Senior Vice President & Head of Quality and Regulatory | 0 | N/A |
| Sanam Pangali | Chief Legal Officer & Corporate Secretary | 0 | 1984 |
| Jack Danilkowicz | Chief Commercial Officer | 0 | N/A |
| Kolbot By | Senior Vice President & Head of Technical Operations | 0 | N/A |
| Philip Nunn | Senior Vice President of Pharmacology & Project Team Leader | 0 | N/A |
| Claire Langrish | Senior Vice President & Head of Immunology and Translational Science | 0 | N/A |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.